Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Sonnet Biotherapeutics News

    1,79 $ 0,00% +0,00 $
    In : 1,6713 € | 23.04.24 22:00:00 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3EUBF
    ISIN: US83548R3030
    US-Symbol: SONN
    Typ: Aktie

    Sonnet Biotherapeutics News

    09.01.23 - PR Newswire
    Thinking about buying stock in SWVL Holdings, Apexigen, Sonnet BioTherapeutics, Spruce Biosciences, or Tilray?
    Thinking about buying stock in SWVL Holdings, Apexigen, Sonnet BioTherapeutics, Spruce Biosciences, or Tilray? PR Newswire
    02.11.22 - PR Newswire
    Thinking about buying stock in Mullen Automotive, Xpeng, Paramount Global, Devon Energy, or Sonnet BioTherapeutics?
    Thinking about buying stock in Mullen Automotive, Xpeng, Paramount Global, Devon Energy, or Sonnet BioTherapeutics? PR Newswire
    01.11.22 - PR Newswire
    Thinking about buying stock in SoFi Technologies, Trip.com, Sonnet BioTherapeutics, Lyft, or Nio?
    Thinking about buying stock in SoFi Technologies, Trip.com, Sonnet BioTherapeutics, Lyft, or Nio? PR Newswire
    31.10.22 - PR Newswire
    Thinking about buying stock in Meta Platforms, Dominion Energy, Roku, Quanergy Systems, or Sonnet BioTherapeutics?
    Thinking about buying stock in Meta Platforms, Dominion Energy, Roku, Quanergy Systems, or Sonnet BioTherapeutics? PR Newswire
    21.09.22 - ACCESSWIRE
    Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010
    The SB101 and SB102 studies have together dosed 19 subjects to date This early review of safety sets the stage for further dose escalation Additional safety and cytokine-​specific ...
    16.09.22 - PR Newswire
    Thinking about buying stock in Sonnet BioTherapeutics, Bank of America, Intel Corp, Cisco Systems, or Meta?
    Thinking about buying stock in Sonnet BioTherapeutics, Bank of America, Intel Corp, Cisco Systems, or Meta? PR Newswire
    16.09.22 - ACCESSWIRE
    Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split
    PRINCETON, NJ / ACCESSWIRE / September 16, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company ...
    15.09.22 - PR Newswire
    Thinking about buying stock in Nabriva Therapeutics, Sonnet BioTherapeutics, Fast Radius, Volcon, or Velo3D?
    Thinking about buying stock in Nabriva Therapeutics, Sonnet BioTherapeutics, Fast Radius, Volcon, or Velo3D? PR Newswire
    14.09.22 - PR Newswire
    Thinking about buying stock in Cisco Systems, Sonnet BioTherapeutics, Nikola Corp, Baudax Bio, or Amyris?
    Thinking about buying stock in Cisco Systems, Sonnet BioTherapeutics, Nikola Corp, Baudax Bio, or Amyris? PR Newswire
    15.08.22 - ACCESSWIRE
    Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update
    Initiation of two clinical trials of SON-1010 in both healthy volunteers and patients with advanced solid tumors Positive preclinical data of SON-1010 combined with anti-PD1 ...
    22.07.22 - ACCESSWIRE
    Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
    Sonnet's first clinical trial with SON-080 is a Phase 1b/2a double-​blind, randomized controlled trial This trial is expected to provide safety data compared to previous IL-6 products, ...
    21.07.22 - ACCESSWIRE
    Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
    Represents Sonnet's second clinical trial with SON-1010 Study expected to provide important PK and PD data for potential additional indications of interest Recruitment initiated ...
    10.06.22 - PR Newswire
    Thinking about buying stock in Applied UV, Sonnet BioTherapeutics, Spirit Airlines, Rigel Pharmaceuticals, or SeaChange?
    Thinking about buying stock in Applied UV, Sonnet BioTherapeutics, Spirit Airlines, Rigel Pharmaceuticals, or SeaChange? PR Newswire
    09.06.22 - PR Newswire
    Thinking about buying stock in Bluejay Diagnostics, Sonnet BioTherapeutics, SeaChange International, Rekor Systems, or Aldeyra Therapeutics?
    Thinking about buying stock in Bluejay Diagnostics, Sonnet BioTherapeutics, SeaChange International, Rekor Systems, or Aldeyra Therapeutics? PR Newswire
    09.06.22 - ACCESSWIRE
    Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
    Tumor volume growth inhibition improvements observed with the combination of SON-1010 (IL12-F H AB) and a commercially available anti-PD1 antibody Combination of SON-...
    02.06.22 - ACCESSWIRE
    Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum
    PRINCETON, NJ / ACCESSWIRE / June 2, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing ...
    10.05.22 - ACCESSWIRE
    Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update
    IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumors SON-080 on track to begin clinical studies by mid-2022 Preclinical data for SON-1010, ...
    13.04.22 - PR Newswire
    Thinking about buying stock in Aterian, Sonnet BioTherapeutics, Gap, Uranium Energy, or Sunshine Biopharma?
    Thinking about buying stock in Aterian, Sonnet BioTherapeutics, Gap, Uranium Energy, or Sunshine Biopharma? PR Newswire
    13.04.22 - ACCESSWIRE
    Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors
    PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-​stage company developing targeted immunotherapeutic drugs, ...
    08.04.22 - ACCESSWIRE
    Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting
    PRINCETON, NJ / ACCESSWIRE / April 8, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-​stage company developing targeted immunotherapeutic drugs, ...

    Newssuche

    Videos

    newspaper
    23.04.24 -2,95%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: UH45D5 Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »